Active Ingredient (In Each Tablet)
Acetaminophen 325mg
The following Structured Product Label (SPL) was submitted to the FDA by Allegiant Health for the product Acetaminophen 325mg (NDC 69168-010). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding active ingredient (in each tablet), purpose, uses, warnings, do not use, ask a doctor before use if user has, ask a doctor or pharmacist before use if, stop use and ask a doctor if, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
Acetaminophen 325mg
Pain reliever/fever reducer
temporary relief of minor aches and pains associated with:
Liver Warning: This product contains acetaminophen. Severe liver damage may occur if
Allergy alert: Acetaminophen may cause severe skin reactions. Symptoms may include:
If a skin reaction occurs, stop use and seek medical help right away.
If you are not sure whether a drug contains acetaminophen, ask a doctor or pharmacist.
liver disease.
the user is taking the blood thinning drug warfarin
If pregnant or breast-feeding, ask a health professional before use.
Keep out of reach of children. In case of accidental overdose, contact a doctor or Poison Control Center immediately. Prompt medical attention is critical for adults as well as for children even if you do not notice any signs or symptoms.
Adults and children 12 years of age and over: Take 2 tablets every 4 to 6 hours.
Do not take more than 10 tablets in 24 hours.
Children 6-11 years of age: Take 1 tablet every 4 to 6 hours as needed.
Do not take more than 5 tablets in 24 hours.
Children under 6 years of age: Do not use this regular strenght product. This will provide more than the recommended dose (overdose) and could cause serious health problems.
corn starch, povidone, pregelatinized starch, sodium starch glycolate, stearic acid
* Please review the disclaimer below.